The Wistar Institute's Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center's Molecular and ...
Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...
Novel method identified protein degraders that target Pin1, a protein involved in pancreatic cancer development.
AstraZeneca, in partnership with the Moi Teaching & Referral Hospital (MTRH), has launched an advanced molecular testing ...
Molecular Partners said it expanded an agreement with Orano Med to develop and market Radio-DARPin therapeutics for the treatment of cancer. The biotechnology company said the new agreement will ...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...
(UCR/Isaac Rodriguez) “This ‘molecular crowbar’ strategy is potentially a promising method in drug discovery and pharmacology ...
News Medical on MSN9d
'Molecular crowbar' protein degradation strategy offers new hope in cancer therapyIn drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins. A University of California, Riverside team of scientists has used a novel approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback